BOSTON--(BUSINESS WIRE)--Manna Molecular, a leading cannabis biotech firm, announced Dr. Harin Padma-Nathan, MD, FRCS, FACS, the world’s foremost clinician in sexual dysfunction FDA trials, has joined the company as its Chief Medical Officer. Dr. Padma-Nathan brings more than 25 years of clinical and medical research experience to Manna Molecular, including overseeing clinical trials of the two biggest blockbuster FDA-approved sexual dysfunction drugs ever made–Viagra® and Cialis®. He has also published extensive research on Viagra®, Caverject® and MUSE® in the New England Journal of Medicine.
“We are thrilled Dr. Padma-Nathan -- the premier world leader in sexual health who has impeccable research credentials and big-time FDA clinical experience -- is joining our company just as we set out to launch our new sexual health and wellness line,” says Manna’s CEO Nial DeMena. “He is exceptionally qualified to help lead the launch of our new product line as new cannabis consumers are demanding more researched and evidence-based commercial cannabis products.”
As Chief Medical Officer, Dr. Padma-Nathan, MD will oversee the development of Manna SX™, a new cannabinoid-based sexual health and wellness line focused on performance and pleasure enhancement for both men and women. Using micronized, multi-lamellar freeze-dried and self-forming liposomal technology, Manna SX™ offers a range of products, including lubricants, pills and tablets and infused “bedroom-safe” consumer packaged goods and consumables.
“The large, multi-lamellar liposomes carry a larger payload and increase real-world efficacy,” said Dr. Padma-Nathan. “It is a completely water-soluble product, and condom compatible as opposed to current cannabis sexual enhancement products. Because our product is plastic tolerant, micronized liposome technology will expand commercial packaging and product options for infused liquid storage, infused beverages, and plastics-derived materials, such as tampons and condoms.”
The company plans to offer and license pre-liposomal lyophilate powder, that enables consumers to infuse beverages at the point-of-consumption. The bioavailability of oral delivery, such as with beverages, will increase efficacy five-to-eight-fold and feature faster onset versus unencapsulated extracts and shorter duration—an important caveat when dosages and serving sizes are regulated state-by-state. The technology comes as close to inhaled delivery as the state-of-the-art science of infusions can come today.
Manna Molecular specializes in delivery platforms and the commercialization of novel cannabis products. The company operates and licenses the Manna Transdermal Patch in 12 states and to several Tier 1 multi-state operators, including Surterra and Sirona.
Manna Molecular plans to offer the beverage infusion packets for licensing in Q1 2019 and the Manna SX™ line will launch its first product line by Q2 of 2019.
About Manna Molecular
Founded in 2015, Manna Molecular Science combines whole-plant cannabis extracts with innovative technology to evolve cannabis medicine for everyday life. The team in their lab includes scientists with decades of experience in pharmaceutical formulation, analytical chemistry, and product development. For more information, please visit http://www.mannamolecular.com/.
